Ireland
--:--IST
Recruiting Phase 3

ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

NCT07687056 · tracked via the Priya Life Science Canada tracker
Phase
Phase 3
Started
2026-08-11
Last updated
2026-10-21

Condition(s) studied

Stroke, Acute IschemicEndovascular ThrombectomyAcute Ischemic Stroke AIS

Investigational drug(s) / intervention(s)

Tenecteplase or Alteplase- depending upon availability at each treating centre →Control

Tenecteplase or Alteplase- depending upon availability at each treating centre: Intra-arterial thrombolysis after endovascular therapy

Control: No intra-arterial thrombolysis after endovascular therapy

Study summary

Study Design and Duration:

This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT. It has a prospective, randomised, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design of up to 1,500 subjects with Acute Ischemic Stroke (AIS) who undergo EVT. Randomisation will be stratified by country/ region, and the IA thrombolytic agent (tenecteplase or alteplase). Minimal sufficient balance algorithm will operate within each stratum to preserve balance on key covariates while maintaining allocation randomness.

Participants will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. Primary outcome data will be determined by simplified, structured method of assessment using the modified Rankin scale (mRS), conducted through centralized telephone interviews or online media performed by central trial personnel blinded to treatment assignment and received.

Domain Interventions:

The intervention group will receive a single dose of local intraarterial thrombolysis using either tenecteplase (at a dose of 0.0625mg/kg; maximum dose of 6.25mg) or alteplase (0.225 mg/kg; maximum dose, 20mg) at the end of EVT procedure plus standard of care while the control group will receive standard of care alone. The selection of the thrombolytic agent will be determined according to local availability. The dose of intraarterial thrombolysis will be increased if the above dose meets prespecified posterior probabilities at the first or second interims.

In all eligible patients:

1. Local intra-arterial thrombolysis using either tenecteplase at a dose of 0.0625mg/kg "maximum dose of 6.25mg" or alteplase "0.225 mg/kg; maximum dose, 20mg\*
2. No intra-arterial thrombolysis.

* The dose of IA thrombolysis may be doubled to 0.125 mg/kg tenecteplase or 0.45 mg/kg alteplase if this dose shows futility at pre-specified interims Randomization will be stratified by country/ region, the IA thrombolytic agent used (tenecteplase or alteplase). IA thrombolysis will be administered as a one-time treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of stroke Exclusion Criteria: There are no platform level exclusion criteria.

Primary outcome measure(s)

  • A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS), — From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner
    Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

Trial sites (13)

FacilityCityRegionStatus
The George Institute for Global Health Sydney Barangaroo Not Yet Recruiting
University of Calgary- Foothills Medical Centre Calgary Alberta Recruiting
University of Alberta Edmonton Alberta Not Yet Recruiting
Kelowna Regional Hospital Kelowna British Columbia Not Yet Recruiting
Royal Columbian Hospital New Westminster British Columbia Not Yet Recruiting
University of British Columbia Vancouver British Columbia Not Yet Recruiting
University of Manitoba - Winnipeg Health Science Centre Winnipeg Manitoba Not Yet Recruiting
Health Sciences North Horizon Sante-Nord Greater Sudbury Ontario Not Yet Recruiting
Ottawa Civic Hospital Ottawa Ontario Not Yet Recruiting
Sunnybrook Health Science Centre Toronto Ontario Not Yet Recruiting
CHUM -Centre Hospitalier de l'Universite de Montreal Montreal Quebec Not Yet Recruiting
CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke) Sherbrooke Quebec Not Yet Recruiting
Royal University Hospital Saskatoon Saskatchewan Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07687056 on ClinicalTrials.gov ↗ ← All trials in Canada